
News|Articles|September 30, 2025
Sensitive LC-MS/MS approach for the quantification of proteolysis targeting chimeras in a biological matrix
Author(s)SCIEX
Key Takeaways
- Personalized treatment strategies have advanced lung cancer brain metastases management, integrating targeted therapies and immunotherapies for improved outcomes.
- Stereotactic radiosurgery and whole-brain radiation therapy are evolving with novel systemic therapies, maintaining their importance in treatment.
PROTACs are protein degraders that harness the cell’s disposal machinery to remove specific targets. Now advancing into clinical trials, they show high potency at nanomolar levels. To support safe and effective drug development, sensitive and selective assays are essential for reliable detection and quantification.
Newsletter
Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.
Trending on LCGC International
1
Navigating Adverse Reactions in GLP-1 Treatment
2
Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling
3
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets
4
Shifting GLP-1 Receptor Agonists from Proteins to Small Molecules
5
